Literature DB >> 22070917

Toll-like receptor 3-mediated tumor invasion in head and neck cancer.

Hui-Ching Chuang1, Chao-Cheng Huang, Chih-Yen Chien, Jiin-Haur Chuang.   

Abstract

OBJECTIVES: Chronic inflammation associated with some infectious agents can lead to cancer. The Toll-like receptor (TLR) family is one of the largest and best-studied families of pathogen-associated molecular patterns. TLR3 recognizes double-stranded RNA and is a major effector of the immune response against viral pathogens.
MATERIALS AND METHODS: We investigated TLR3 protein expression in 153 oral squamous cell carcinoma (OSCC) specimens using tissue microarray. Furthermore, we used polyinosinic-polycytidylic acid (poly I:C) to stimulate head and neck cancer cells and an inhibitor of endosomal acidification bafilomycin A1 to block the TLR 3 signaling pathway to clarify the role of TLR 3 in OSCC.
RESULTS: Cytoplasmic TLR3 staining was observed in the vast majority of OSCC tissues (73.2%). Strong TLR3 expression was significantly correlated with patients whose tumors were poorly differentiated (P=0.028) and with perineural invasion (P=0.023). Three of the four head and neck cell lines tested (Fadu, OC2, and SCC4) expressed TLR3 mRNA, although at various levels. The stimulation of TLR3-expressing OC2 cells with poly I:C caused the phosphorylation of IFN regulatory factor 3 and IκB and sequentially induced the secretion of interleukin-6 and chemokine (C-C motif) ligand 5 (CCL5) in a dose- and time-dependent manner. Moreover, poly I:C stimulation promoted CCL5-mediated migration in OC2 cells.
CONCLUSIONS: In this report, we provide a novel mechanism for tumor invasion and the TLR3-dependent inflammatory response that could have therapeutic implications for OSCC. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22070917     DOI: 10.1016/j.oraloncology.2011.10.008

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  12 in total

1.  Interferon response factor 3 is crucial to poly-I:C induced NK cell activity and control of B16 melanoma growth.

Authors:  Tyler C Moore; Phyllis M Kumm; Deborah M Brown; Thomas M Petro
Journal:  Cancer Lett       Date:  2013-12-22       Impact factor: 8.679

Review 2.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

3.  Targeting Toll-Like Receptors for Cancer Therapy.

Authors:  Marc J Braunstein; John Kucharczyk; Sylvia Adams
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 4.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

Review 5.  Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.

Authors:  Marconi Rego Barros; Talita Helena Araújo de Oliveira; Cristiane Moutinho Lagos de Melo; Aldo Venuti; Antonio Carlos de Freitas
Journal:  J Immunol Res       Date:  2018-05-02       Impact factor: 4.818

6.  Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.

Authors:  Lugain Alkurdi; François Virard; Béatrice Vanbervliet; Kathrin Weber; Florent Toscano; Marc Bonnin; Nolwenn Le Stang; Sylvie Lantuejoul; Olivier Micheau; Toufic Renno; Serge Lebecque; Yann Estornes
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

7.  EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.

Authors:  T Kumai; Y Matsuda; K Oikawa; N Aoki; S Kimura; Y Harabuchi; E Celis; H Kobayashi
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

Review 8.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

Review 9.  Toll-like receptors and skin cancer.

Authors:  Erin M Burns; Nabiha Yusuf
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

Review 10.  Toll-like receptors and cancer, particularly oral squamous cell carcinoma.

Authors:  Alison Mary Rich; Haizal Mohd Hussaini; Venkata P B Parachuru; Gregory J Seymour
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.